Clinical research

Clinical effect of recombinant human granulocyte-macrophage colony stimulating factor gel on donor site after medium to thickness skin transplantation in patients with diabetes

  • Wei-dong XIA ,
  • Guang-yi CHEN ,
  • Wen-tong DAI ,
  • Sheng ZHAO ,
  • Su LI ,
  • Cai LIN
Expand
  • Burn Wound Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
LIN Cai, E-mail: 13025092850@163.com.

Online published: 2021-10-22

Abstract

Objective

·To explore the effect of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) gel on the donor site of patients with diabetic skin ulcer after medium to thickness skin transplantation.

Methods

·Seventy-four patients with diabetic skin ulcer who were admitted to the Burn Wound Center, the First Affiliated Hospital of Wenzhou Medical University from March 2016 to April 2021 and underwent medium to thickness skin transplantation were analyzed retrospectively. All patients were given active monitoring, drug control of blood glucose, appropriate symptomatic and supportive treatment such as anti-inflammatory, fluid rehydration and nutrition. According to the different treatment methods of the donor site, patients treated with rhGM-CSF gel in the skin donor sites were assigned to the rhGM-CSF group (38 cases); patients treated with routine dressing change in the skin donor sites were assigned to the control group (36 cases). The healing rate and the complete healing time of the donor site on the 8th and 14th day after treatment were calculated respectively in the two groups, and the changes of laboratory examination results before and after treatment in the rhGM-CSF group were compared.

Results

·There were no significant differences in age, pre-treatment albumin level, glycated hemoglobin level and the area of donor site between the two groups. On the 8th and 14th day after treatment, the wound healing rates of the rhGM-CSF group were (53±19) % and (92±14) %, respectively, which were significantly higher than (35±18) % and (77±20) % of the control group, and the difference was statistically significant (t=-4.159, P=0.000; t=-3.462, P=0.000). The complete healing time of the donor site in the rhGM-CSF group was (14±3) d, which was shorter than (16±3) d in the control group (t=3.452, P=0.000). There was no significant difference in platelet count, the levels of hemoglobin, glutamic-pyruvic transaminase, and creatinine. Leukocyte count after treatment was lower than before treatment (Z=-3.491, P=0.000), but both of them were in the normal reference range and had no clinical significance.

Conclusion

·The application of rhGM-CSF gel to the donor site after medium to thickness skin transplantation in diabetic skin ulcer patients can promote the healing of wounds, shorten the wound healing time, and has certain safety. It is worthy of application and popularization.

Cite this article

Wei-dong XIA , Guang-yi CHEN , Wen-tong DAI , Sheng ZHAO , Su LI , Cai LIN . Clinical effect of recombinant human granulocyte-macrophage colony stimulating factor gel on donor site after medium to thickness skin transplantation in patients with diabetes[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(11) : 1498 -1501 . DOI: 10.3969/j.issn.1674-8115.2021.11.014

References

1 Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035[J]. Diabetes Res Clin Pract, 2014, 103(2): 137-149.
2 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
3 谷红艳. 糖尿病足的预防和护理研究进展[J]. 继续医学教育, 2020, 34(4): 124-126.
4 程玉霞, 赵凤卉, 朱平, 等. 复发性糖尿病足溃疡的危险因素分析[J]. 北京医学, 2019, 41(11): 1024-1027.
5 薛春利, 胡志成, 杨祖贤, 等. 异体脱细胞真皮基质治疗糖尿病足溃疡临床效果荟萃分析[J]. 中华烧伤杂志, 2016, 32(12): 725-729.
6 李玉华. 糖尿病足的外科治疗[J]. 糖尿病新世界, 2014, 34(14): 45.
7 宋来权, 赵红翠. 糖尿病足创面愈合过程的动态组织学特征[J]. 智慧健康, 2017, 3(5): 181-182.
8 宋萌, 陈庆杰, 王宏宇, 等. 外用rhGM-CSF凝胶联合磺胺嘧啶银乳膏治疗小面积深Ⅱ度难愈创面的疗效及安全性[J]. 解放军医药杂志, 2019, 31(5): 67-70.
9 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J]. 中国糖尿病杂志, 2014, 22(8): 2-42.
10 司向, 翟屹, 朱晓磊, 等. 2014年中国慢性非传染性疾病预防控制能力评估[J]. 中华流行病学杂志, 2019, 40(2): 231-236.
11 Barrett EJ, Liu ZQ, Khamaisi M, et al. Diabetic microvascular disease: an endocrine society scientific statement[J]. J Clin Endocrinol Metab, 2017, 102(12): 4343-4410.
12 Chin JS, Madden L, Chew SY, et al. Drug therapies and delivery mechanisms to treat perturbed skin wound healing[J]. Adv Drug Deliv Rev, 2019, 149-150: 2-18.
13 Yan DX, Liu S, Zhao XC, et al. Recombinant human granulocyte macrophage colony stimulating factor in deep second-degree burn wound healing[J]. Medicine (Baltimore), 2017, 96(22): e6881.
14 Zhao JL, Chen L, Shu B, et al. Granulocyte-macrophage colony-stimulating factor influences angiogenesis by regulating the coordinated expression of VEGF and the Ang/Tie system[J]. PLoS One, 2014, 9(3): e92691.
15 Krzyszczyk P, Schloss R, Palmer A, et al. The role of macrophages in acute and chronic wound healing and interventions to promote pro-wound healing phenotypes[J]. Front Physiol, 2018, 9: 419.
16 Wu F, Dai LL, Geng L, et al. Practically feasible production of sustained-release microspheres of granulocyte-macrophage colony-stimulating factor (rhGM-CSF)[J]. J Control Release, 2017, 259: 195-202.
Outlines

/